CHA ÀÇ°úÇдëÇб³ Â÷º´¿ø professor

±³¼ö´Ô»çÁø
  • ÀüÈ«Àç
  • ¾Ï¼¾ÅÍÀå
  • ¼Ò ¼Ó: ºÐ´çÂ÷º´¿ø
  • Àü¹®ºÐ¾ß : °£¾Ï/Ãé´ãµµ¾Ï
  • Á÷ À§: ºÎ±³¼ö(¾Ï¼¾ÅÍÀå)
  • ¸Þ ÀÏ: ºñ°ø°³
  • Àü È­: 1577-4488
  • ÆÑ ½º:
  • ÁÖ ¼Ò: °æ±âµµ ¼º³²½Ã ºÐ´ç±¸ ¾ßžµ¿ 351¹øÁö
  • ȨÆäÀÌÁö:
  • ·Î±×ÀÎ

ÅǸ޴º

ÁÖ¿ä¹ßÇ¥³í¹®

ÁÖ¿ä¹ßÇ¥³í¹®
¹øÈ£ ±¸ºÐ Á¦¸ñ
253 (±¹¿Ü)SCI Combination of Irreversible Electroporation and STING Agonist for Effective Cancer Immunotherapy
252 (±¹¿Ü)SCI Real-World Experience with Pembrolizumab Treatment in Patients with Heavily Treated Recurrent Gynecologic Malignancies
251 (±¹¿Ü)SCI "Long-term safety and tolerability of subretinal transplantation of embryonic stem cell-derived retinal pigment epithelium in Asian Stargardt disease patients"
250 (±¹¿Ü)SCI MED-TMA: A clinical decision support tool for differential diagnosis of TMA with enhanced accuracy using an ensemble method
249 (±¹¿Ü)SCIE Association between Five Common Plasminogen Activator Inhibitor-1 (PAI-1) Gene Polymorphisms and Colorectal Cancer Susceptibility
248 (±¹¿Ü)SCI Distinct genetic profile with recurrent population-specific missense variants in Korean adult atypical hemolytic uremic syndrome
247 (±¹¿Ü)SCIE Targeting Actomyosin Contractility Suppresses Malignant Phenotypes of Acute Myeloid Leukemia Cells
246 (±¹¿Ü)SCI Korean red ginseng for cancer-related fatigue in colorectal cancer patients with chemotherapy: A randomised phase III trial
245 (±¹¿Ü)SCI Association between KCNQ2, TCF4 and RGS18 polymorphisms and silent brain infarction based on whole?exome sequencing
244 (±¹¿Ü)±âŸ REACH-2: First Biomarker-Based Anti-Angiogenic Therapy in Patients With Advanced Hepatocellular Carcinoma
ÀÌÀüÆäÀÌÁö À̵¿ 1 2 3 4 5 6 7 8 9 10 ´ÙÀ½ÆäÀÌÁö À̵¿
Copyright ¨Ï chamc, All rights reserved.

ºü¸£°í Æí¸®ÇÑ ÀÎÅÍ³Ý Áø·á¿¹¾à

  • °­³²Â÷º´¿ø
  • ºÐ´çÂ÷º´¿ø
  • ºÐ´çÂ÷¿©¼ºº´¿ø
  • ±¸¹ÌÂ÷º´¿ø
  • ¿©¼ºÀÇÇבּ¸¼Ò
  • Â÷¿ò

ÀüÈ­¹®ÀÇ

  • °­³²Â÷º´¿ø 02.3468.3000
  • ºÐ´çÂ÷º´¿ø 031.780.5000
  • Â÷¿ò 02.3015.5300
  • ±¸¹ÌÂ÷º´¿ø 054.450.9700
  • ´ë±¸¿©¼ºÂ÷º´¿ø 02.222.4200
  • °­³²°ÇÁø¼¾ÅÍ 02.2191.3900
  • ºÐ´çÁ¾ÇÕ°Ç°­ÁõÁø¼¾ÅÍ 031.780.5940
  • ½ºÆ÷·º½º °ÇÁø¼¾ÅÍ 02.3473.2111
  • ±¸¹ÌÂ÷º´¿ø°ÇÁø¼¾ÅÍ 054.450.9800
  • ȨÆäÀÌÁö°ü¸®ÀÚ 031.780.1729